Monday, December 11, 2017 10:15 PM ET
Significant Insider Selling in Shares of Vertex Pharmaceuticals (VRTX) Continues
There was a significant sale of shares of Vertex Pharmaceuticals by an insider today, as indicated in a form 4 document filed with the SEC. One insider — Dr Jeffrey M Leiden, Director and Officer — sold 125,000 shares in the company having a market value of approximately $17,668,896. There have been 6 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 175,640 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 300,640 shares and have averaged 42,949 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at Vertex Pharmaceuticals is higher than its 278-company peer group average. The Bio Therapeutic Drugs peer group saw 340 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by Vertex Pharmaceuticals insiders is lower than its peers. Within the peer group there were 37,772,262 shares purchased and 42,634,136 shares sold with company insiders disposing of 14,300 shares on average over this time period.
The data used in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.